Revolution Medicines at Goldman Sachs 45th Annual Global Healthcare Conference

Revolution Medicines Inc., based in Redwood City, California, and listed on Nasdaq under the symbol RVMD, is a clinical-stage oncology company specializing in developing targeted therapies for patients with RAS-addicted cancers. On June 5, 2024, the company announced that its Chief Executive Officer and Chairman, Mark A. Goldsmith, M.D., Ph.D., will be a featured speaker at the Goldman Sachs 45th Annual Global Healthcare Conference.

The conference will take place from June 10 to June 13, 2024, at the Loews Miami Beach Hotel in Miami, Florida. Goldsmith's fireside chat is scheduled for 2:40 p.m. ET on Wednesday, June 12, 2024. Interested parties can access a live webcast of the discussion via the "Events & Presentations" page on the Revolution Medicines website. A replay will also be available on the same page for at least two weeks following the event.

Revolution Medicines focuses on creating innovative therapies that target RAS-addicted cancers. The company's research and development pipeline includes a variety of RAS(ON) inhibitors. These inhibitors are designed to suppress numerous oncogenic variants of RAS proteins, making them versatile tools in oncology treatment strategies.

Current clinical developments include:
- RMC-6236: A multi-selective RAS(ON) inhibitor.
- RMC-6291: A G12C-selective RAS(ON) inhibitor.
- RMC-9805: A G12D-selective RAS(ON) inhibitor.

The company is also exploring additional RAS(ON) mutant-selective inhibitors such as:
- RMC-5127, targeting the G12V mutation.
- RMC-0708, targeting the Q61H mutation.
- RMC-8839, targeting the G13C mutation.

Furthermore, Revolution Medicines is developing RAS companion inhibitors like:
- RMC-4630, which targets SHP2.
- RMC-5552, which targets mTORC1/4EBP1.

These developments highlight Revolution Medicines' commitment to advancing cancer treatment through precision medicine and targeted therapies. The company's participation in the Goldman Sachs conference underscores its ongoing efforts to engage with the broader healthcare and investor community, providing updates on their progress and future plans.